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ABSTRACT
Triggering receptor expressed on myeloid cells-1 (TREM-1) is produced and up-regulated by
exposure of myeloid cells to lipopolysaccharides or other components of either bacterial or fungal
origin, which causes it to be strongly expressed on phagocytes that accumulate in inflamed areas.
Because TREM-1 participates in septic shock and in amplifying the inflammatory response to
bacterial and fungal infections, we believe it could be an immunohistochemical marker for
postmortem diagnosis of sepsis. We tested the anti-TREM-1 antibody in 28 cases of death by
septic shock and divided them into two groups. The diagnosis was made according to the criteria
of the Surviving Sepsis Campaign. In all cases, blood cultures were positive. The first group was
comprised subjects that presented high ante-mortem serum procalcitonin and the soluble form of
TREM-1 (s-TREM-1) values. The second group comprised subjects in which s-TREM-1 was not
measured ante-mortem. We used samples of brain, heart, lung, liver and kidney for each case to
test the anti-TREM-1 antibody. A semiquantitative evaluation of the immunohistochemical find-
ings was made. In lung samples, we found immunostaining in the cells of the monocyte line in 24
of 28 cases, which suggests that TREM-1 is produced principally by cells of the monocyte line. In
liver tissue, we found low TREM-staining in the hepatocyte cytoplasm, duct epithelium, the portal-
biliary space and blood vessel. In kidney tissue samples, we found the TREM-1 antibody immu-
nostaining in glomeruli and renal tubules. We also found TREM-1 staining in the lumen of blood
vessels. Immunohistochemical staining using the anti-TREM-1 antibody can be useful for post-
mortem diagnosis of sepsis.
KEYWORDS
Immunohistochemistry;
marker; postmortem
diagnosis; sepsis; septic
myocardial dysfunction;
septic shock; triggering
receptor expressed on
myeloid cells-1
Triggering receptor expressed on myeloid cells-1
(TREM-1) belongs to the immunoglobulin superfam-
ily (Barraud and Gibot 2011). It is expressed on neu-
trophils and mature monocytes, and the genes that
code it are grouped on human chromosome 6.
TREM-1 is expressed also on nonmyeloid cells, such
as epithelial or endothelial cells (Bouchon et al. 2000).
TREM-1 is produced and up-regulated by exposure of
myeloid cells to lipopolysaccharides or other microbial
components of either bacterial or fungal origin, which
causes it to be strongly expressed on phagocytes that
accumulate in inflamed areas (Bleharski et al. 2003;
Yuan et al. 2012).
TREM-1 has an alternatively spliced variant that lacks
the transmembrane region, which results in secretion of
the receptor in a soluble form (s-TREM-1) (Weiss et al.
2017). s-TREM-1 is a 17-kDa fragment that is detectable
in body fluids such as blood, broncho-alveolar lavage
and cerebrospinal fluid. This molecule can be dosed in
biological fluids (Brenner et al. 2016). Plasma levels of
s-TREM-1 > 60 ng/ml seem to be more accurate than
other clinical or laboratory tests for identifying patients
with an ongoing infection (Giamarellos-Bourboulis et al.
2006). s-TREM-1 is released by activated phagocytes and
can be found in plasma, pleural fluid, cerebrospinal
liquor and urine (Arízaga-Ballesterosa et al. 2015;
Latour-Pérez et al. 2010; Wu et al. 2012).
Combined with other markers, s-TREM-1 appears
to be valuable for differential diagnosis of a non-
infective sepsis with systemic inflammatory response
syndrome (SIRS) (Bouchon et al. 2001; Oku et al.
2013). In the forensic field, reliable diagnosis of
sepsis may be even more difficult owing to unavail-
able medical records at autopsy, nonspecific autopsy
and histological findings including myocardial
ischemia, pulmonary edema, hypoxic liver damage,
mesenteric ischemia, gastrointestinal hemorrhage,
spleen infarction, kidney ischemia and brain edema
that may have either an infectious or non-infectious
origin.
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Because of the crucial role that TREM-1 plays in
increasing septic shock and amplifying the inflamma-
tory response to bacterial and fungal infections, we
suspect that it could be a useful immunohistochemical
marker for postmortem diagnosis of sepsis.
Material and methods
Our data are covered by the general authorization to
process personal data for scientific research purposes
granted by the Italian Data Protection Authority
(1March 2012 as published in Italy’s Official Journal
no. 72 dated March 26 2012), because the data do not
include significant personal information concerning the
subjects. Our study does not involve the application of
experimental protocols; therefore, it does not require
approval by institutional and/or licensing committees.
In all cases, local prosecutors opened an investigation
and ordered that an autopsy be performed to clarify the
exact cause of death. We selected seven women and 21
men, mean age 58.2 years, who died from septic shock
with an ante-mortem diagnosis of sepsis. The diagnosis
was made according to the criteria of the Surviving
Sepsis Campaign (Singer et al. 2016). Blood cultures
were positive in all cases. We subdivided the cases into
two groups. The first group comprised 14 subjects that
presented high ante-mortem serum procalcitonin and
s-TREM-1 values. The diagnostic evaluation of
s-TREM-1 was performed using receiver operating char-
acteristic (ROC) analysis. Areas under the curve (AUCs)
were calculated. The second group comprised 14 sub-
jects in which s-TREM-1 was not measured ante-
mortem. Data concerning the subjects are given in
Table 1.
We chose non-infective cases as a control group of
adults (n = 14; six women, eight men, mean age
49.4 years) with no clinical history or macroscopic or
microscopic signs of infection whose deaths were char-
acterized by suddenness. We tested the anti-TREM-1
antibody on subject that died from opioid overdose
(n = 5), hanging (n = 4), car accident (n = 4) and
sudden cardiac death (n = 1). The postmortem interval
was ≤ 36 h in each case. We used five samples, brain,
heart, lung, liver and kidney for each case.
Samples, 8 cm2, of each organ from each case were
fixed in 10% buffered formalin, then washed with phos-
phate-buffered saline (PBS) and subsequent dehydra-
tion was carried out using a graded alcohol series. After
dehydration, samples were cleared in xylene, and
embedded in paraffin. Sections were cut at 4 μm,
mounted on slides and covered with 3-amminopropyl-
triethoxysilane (Fluka, Buchs, Switzerland). A routine
microscopic histopathological study was performed
after hematoxylin and eosin (H & E) staining (Fischer
et al. 2008).
To test the anti-TREM-1 antibody (clone
L5-B8.2A12.3A12; Novusbio, Abingdon, UK), we used
a biopsy sample of stomach wall from a living patient
with chronic gastritis caused by a Helicobacter pylori
infection. The biopsy sample was fixed in 10% buffered
formalin, then washed with PBS and subsequent dehy-
dration was carried out using a graded alcohol series.
After dehydration, samples were cleared in xylene and
embedded in paraffin. Sections were cut at 4 μm,
mounted on slides and covered with 3-amminopropyl-
triethoxysilane (Fluka, Buchs, Switzerland). The sec-
tions were re-hydrated through graded alcohols and
incubated for 20 min in methanol containing 10%
H2O2 to block endogenous peroxidases. The sections
were pretreated with citrate buffer (10 mM sodium
citrate, pH 6.0), incubated with the anti-TREM-1 anti-
body (clone L5-B8.2A12.3A12; Novusbio, Abingdon,
UK) diluted 1:500, then treated with BrightVision®
Table 1. Ante-mortem serum and main autopsy and histology
findings.
Case
PCT
ante-
mortem
s-TREM-
1
ante-
mortem
Ante-mortem
microbiology in blood
Main autopsy and
histology findings
1 29.8 120.0 Acinetobacter
baumannii + S. aureus
Pneumonia
2 17.34 80.4 E. coli Peritonitis
3 16.22 64.15 K. pneumoniae Pneumonia
4 37.04 100.74 S. aureus Necrotizing fasciitis
+ pneumonia
5 25.15 75.20 E. faecalis + E. coli Peritonitis
6 20.15 88.50 St.epidermidis +
S. aureus
Pneumonia-hip
prosthesis infection
7 33.08 93.13 E. faecalis + E. coli Abdominal and
pelvic infection
8 28.09 97.90 E. coli
+ P. aeruginosa
Pneumonia
+ urinary infection
9 18.64 68.75 Acinetobacter
baumannii
Pneumonia
10 30.44 98.00 K. pneumoniae Pneumonia
11 16.44 66.88 S. aureus Pneumonia
12 32.42 90.26 P. aeruginosa Pneumonia
13 18.64 86.68 E. coli Peritonitis
14 34.76 98.24 K. pneumoniae Pneumonia
15 K. pneumoniae Pneumonia
16 P. aeruginosa Pneumonia
17 E. coli + K. pneumoniae Abdominal and
pelvic infection
18 P. aeruginosa Necrotizing fasciitis
19 L. monocytogenes
+ K. Pneumoniae
Pneumonia
20 Stenotrophomonas
maltophilia
+ P. aeruginosa
Pneumonia
21 P. aeruginosa Pneumonia
22 P. aeruginosa
+ S. Aureus
Pneumonia
+ peritonitis
23 Acinetobacter baumanii Pneumonia
24 E. Coli Peritonitis
25 Acinetobacter baumanii Pneumonia
26 K. pneumoniae Pneumonia
27 L. Monocytogenes Pneumonia
28 E. Coli Peritonitis
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PolyHRP-anti rabbit (Vector Labs, Peterborough, UK)
and developed using 1% H2O2 and DAB (Sigma-
Aldrich, Darmstadt, Germany) in 0.05 M Tris-HCl
(pH 7.9) (Yuan et al. 2014). The anti-TREM-1 exhibited
staining in the stomach epithelium and glands, which
served as a positive control. All postmortem samples
from brain, heart, lung, liver and kidney, were immu-
nostained using the method described above for the
stomach wall biopsy.
For quantitative analysis, in each immunohisto-
chemical section we made 20 observations in different
fields/slide. The TREM-1 stained cells were counted at
40 x using a light microscope coupled to a high resolu-
tion color video camera. The number of stained cells
was divided by the total number of cells and multiplied
x100. The immunohistochemical positivity score was
defined as: 0, nuclear and/or cytoplasm staining absent;
1, nuclear and/or cytoplasmic staining, 25%; 2, nuclear
and/or cytoplasmic staining, 50%; 3, nuclear and/or
cytoplasmic staining, 75%; 4, nuclear and/or cytoplasm
staining, 100%. We also quantified immunohistochem-
ical staining in blood vessel as: 0, absent; 1, low, 25%; 2,
sufficient, 50%; 3, good, 75%; 4, considerable, 100%. A
subjective scoring system for the staining intensity of
cells was defined. Five degrees of intensity were defined
as: 0, absent; 1, low, 25%; 2, sufficient, 50%; 3, good,
75%; 4, considerable, 100%). The most intense colora-
tion, grade 5, was that of the stomach wall sample with
chronic gastritis that was used as the positive control.
In cases of heterogeneous intensity, we considered the
prevailing intensity. All evaluations were performed in
a double blind manner. In cases of divergent scoring, a
third observer decided the final score.
Results
Our findings are summarized in Tables 2 and 3. We found
blood vessel immunostaining in kidney tissue samples in 25
cases (Figure 1a). In lung, we found clear staining in lumen
of the blood vessels and cytoplasm of myelomonocytes in
24 of 28 cases (Figure 1b). Inmyocardial samples, we found
clear immunostaining in blood vessels and no staining of
the cytoplasmornucleus ofmyocardial cells (Figure 1c).No
anti-TREM-1 staining was found in any brain samples or
nuclei of nerve cells; we found blood vessel staining in all
cases (Figure 1d). In lung samples we found immunostain-
ing in the cells of themonocyte line in 24 of 28 cases, which
suggests that TREM-1 might be produced principally by
cells of the monocyte line (Figure 2a). We found little
staining in hepatocytes of the liver in 21 of 28 cases
(Figure 2b). In 14 cases, immunostaining appeared in the
duct epithelium or in the portal-biliary space, and in 18
cases we found immunostaining in the blood vessels. In 25
of 28 kidney tissue samples, we found immunostaining in
the glomeruli (Figure 3a), in 20 cases we found staining in
the renal tubules and in 25 cases we found staining of blood
vessels (Figure 3b).
Our findings for the two groups were similar, but the
first group showed a greater immunohistochemical
staining and intensity. The anti-TREM-1 antibody
exhibited no reaction in organs or blood vessels of
cadavers who died from non-infective causes (control
group).
Finally, we detected greater TREM1 staining in the
lumen of the blood vessels of first group with docu-
mented ante-mortem s-TREM-1 concentrations
(Figure 4a–d).
Discussion
We used an experimental model and immunohisto-
chemistry to conduct an investigation of postmortem
TREM-1 expression. Various immunohistochemical
markers have been used to investigate cases of sepsis,
especially with regard to the lung, including markers
for E-selectin, very late antigen 4 (VLA-4), intracellular
adhesion molecule 1 (ICAM-1) and lactoferrin (Müller
et al. 2008; Herwig et al. 2013; Galassi et al. 2018).
Tumor necrosis factor alpha (TNF- α), interleukin-1
beta (IL-1 β) and interleukin-6 (IL-6) are found inter-
mittently or briefly during an inflammatory response
and during sepsis (Carsin et al. 1997). We reported
earlier that anti-procalcitonin antibody can be a valu-
able tool for postmortem diagnosis of sepsis (Maiese
et al. 2017). Nevertheless, definitive techniques that can
be used to make a postmortem diagnosis of sepsis are
lacking. Macroscopic and microscopic pathological
findings are nonspecific and may be inadequate to
render a definitive diagnosis for forensic purposes
when clinical documentation is lacking (Tsokos 2007).
Gibot et al. (2004) reported the concentrations of
C-reactive protein (CRP), procalcitonin (PCT) and
TREM-1 in the plasma of 76 patients in intensive care
units. These markers were stronger in infected patients
than in patients who did not present with SIRS. The
plasma soluble TREM-1 levels had the greatest discrimi-
native value, with an area under the receiver-operating
characteristic curve of 0.97, followed by procalcitonin
(area under the curve = 0.85) and C-reactive protein
(area under the curve = 0.77). At a cutoff level of
60 ng/ml (ELISA Human TREM-1 Quantikine ELISA
Kit, R&D Systems, Minneapolis, MN; sensitivity:
15.2 pg/ml), soluble TREM-1 yielded a sensitivity of
96%, a specificity of 89%, a positive predictive value of
94% and a negative predictive value of 93% using
StatView software (Abacus Concepts, Berkeley, CA) for
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the statistical analysis; a 2-tailed p value ≤ 0.05 was
considered statistically significant). Rivera-Chavez and
Minei (2009) reported an s-TREM-1 cut-off value of
230pg/ml, which yielded a sensitivity of 98% and speci-
ficity of 91% for differentiating patients with SIRS from
those with infection. Patients with infection had signifi-
cantly higher s-TREM-1 concentrations than patients
with SIRS (median 398 pg/ml vs. 78 pg/ml, respectively).
Wang and Chen (2011) reported findings concern-
ing 32 septic patients and 24 patients affected by SIRS
in intensive care units. Compared to the SIRS group,
s-TREM-1 was significantly increased in the sepsis
group. In addition to its use as a diagnostic biomarker,
s-TREM-1 concentration can used to determine the
prognosis of septic patients. Gibot et al. (2005) mea-
sured plasma s-TREM-1 concentration together with
monocyte expression of TREM-1 in 63 septic patients
to determine prognosis.
Promising results with s-TREM-1 as diagnostic sep-
sis marker have been reported. Brenner et al. (2016)
reported that the plasma level of s-TREM-1 was a better
biomarker for identifying patients with septic shock
than the most commonly used acute phase proteins,
CRP and PCT.
Gibot et al. (2007) reported that measurement of serum
PCT together with s-TREM-1 concentrations could be
useful for detecting nosocomial sepsis. Aksaray et al.
(2016) also reported that s-TREM-1 and PCT are excellent
markers for early diagnosis of sepsis. Although further
studies are required to confirm them, our preliminary
findings indicate that s-TREM-1 could enable postmortem
diagnosis of sepsis with good sensitivity and specificity.
Table 2. Qualitative and quantitative results for immunohistochemical staining for TREM 1 and ante-mortem s-TREM values: group 1.
Case Brain Heart Lung Liver Kidney
1 Quantitative 0; V 4
Qualitative 3
Quantitative 0; V 3
Qualitative 3
Quantitative macrophages 4(c); V 4
Qualitative 4
Quantitative hepatocytes 3 (c)
Bile ducts 4; V 3
Qualitative 3
Quantitative
glomeruli 4 tubules 3; V 4
Qualitative 3
2 Quantitative 0; V 1
Qualitative 1
Quantitative 0; V 2
Qualitative 2
Quantitative macrophages 3(c); V 2
Qualitative 2
Quantitative hepatocytes 2 (c)
Bile ducts 2; V 1
Qualitative 2
Quantitative
glomeruli 2 tubules 1; V 2
Qualitative 1
3 Quantitative 0; V 1
Qualitative 1
Quantitative 0; V 1
Qualitative 1
Quantitative macrophages 1(c); V 2
Qualitative 2
Quantitative 0; V 0
Qualitative 0
Quantitative
glomeruli 1 tubules 0; V 1
Qualitative 1
4 Quantitative 0; V 3
Qualitative 3
Quantitative 0; V 3
Qualitative 4
Quantitative macrophages 4 (c); V 3
Qualitative 4
Quantitative hepatocytes 2 (c)
Bile ducts 1; V 2
Qualitative 3
Quantitative
glomeruli 3 tubules 2; V 3
Qualitative 2
5 Quantitative 0; V 2
Qualitative 1
Quantitative 0; V 1
Qualitative 1
Quantitative macrophages 1 (c); V 2
Qualitative 1
Quantitative 0; V 0
Qualitative 0
Quantitative
glomeruli 1 tubules 0; V 1
Qualitative 1
6 Quantitative 0; V 1
Qualitative 2
Quantitative 0; V 2
Qualitative 1
Quantitative macrophages 3 (c); V 2
Qualitative 3
Quantitative hepatocytes 1 (c)
Bile ducts 0; V 1
Qualitative 2
Quantitative
Glomeruli 2 tubules 2; V 2
Qualitative 2
7 Quantitative 0; V 3
Qualitative 2
Quantitative 0; V 1
Qualitative 2
Quantitative macrophages 3 (c); V 3
Qualitative 3
Quantitative hepatocytes 1 (c)
Bile ducts 0; V 1
Qualitative 2
Quantitative
glomeruli 2 tubules 2; V 2
Qualitative 2
8 Quantitative 0; V 3
Qualitative 3
Quantitative 0; V 2
Qualitative 2
Quantitative macrophages 3 (c); V 3
Qualitative 3
Quantitative hepatocytes 2 (c)
Bile ducts 2; V 2
Qualitative 2
Quantitative
glomeruli 2 tubules 2; V 3
Qualitative 2
9 Quantitative 0; V 1
Qualitative 1
Quantitative 0; V 2
Qualitative 2
Quantitative macrophages 3(c); V 2
Qualitative 2
Quantitative hepatocytes 2 (c)
Bile ducts 2; V 1
Qualitative 2
Quantitative
glomeruli 2 tubules 1; V 2
Qualitative 1
10 Quantitative 0; V 1
Qualitative 1
Quantitative 0; V 1
Qualitative 1
Quantitative macrophages 1(c); V 2
Qualitative 2
Quantitative 0; V 0
Qualitative 0
Quantitative
glomeruli 1 tubules 0; V 1
Qualitative 1
11 Quantitative 0; V 3
Qualitative 3
Quantitative 0; V 3
Qualitative 4
Quantitative macrophages 4 (c); V 3
Qualitative 4
Quantitative hepatocytes 2 (c)
Bile ducts 1; V 2
Qualitative 3
Quantitative
glomeruli 3 tubules 2; V 3
Qualitative 2
12 Quantitative 0; V 2
Qualitative 1
Quantitative 0; V 1
Qualitative 1
Quantitative macrophages 1 (c); V 2
Qualitative 1
Quantitative 0; V 0
Qualitative 0
Quantitative
glomeruli 1 tubules 0; V 1
Qualitative 1
13 Quantitative 0; V 1
Qualitative 2
Quantitative 0; V 2
Qualitative 1
Quantitative macrophages 3 (c); V 2
Qualitative 3
Quantitative hepatocytes 1 (c)
Bile ducts 0; V 1
Qualitative 2
Quantitative
glomeruli 2 tubules 2; V 2
Qualitative 2
14 Quantitative 0; V 3
Qualitative 2
Quantitative 0; V 1
Qualitative 2
Quantitative macrophages 3 (c); V 3
Qualitative 3
Quantitative hepatocytes 1 (c)
Bile ducts 0; V 1
Qualitative 2
Quantitative
gomeruli 2 tubules 2; V 2
Qualitative 2
V, intravascular staining; n, nuclear staining; c, cytoplasm staining. For quantitative analysis, the TREM-1 stained cells were counted and divided by the total
number of cells and multiplied x 100. Immunohistochemical positivity score was defined as: 0, nuclear and/or cytoplasm staining absent; 1, nuclear and/or
cytoplasmic staining, 25%; 2, nuclear and/or cytoplasmic staining, 50%; 3, nuclear and/or cytoplasmic staining, 75%; 4, nuclear and/or cytoplasm staining,
100%. Immunohistochemical staining in blood vessel was quantified as: 0, absent; 1, low, 25%; 2, sufficient, 50%; 3, good, 75%; 4, considerable, 100%. Five
degrees of staining intensity were defined as: 0, absent; 1, low, 25%; 2, sufficient, 50%; 3, good, 75%; 4, considerable.
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Table 3. Qualitative and quantitative results for immunohistochemical staining for TREM 1: group 2.
CASE Brain Heart Lung Liver Kidney
Case 1 Quantitative 0; V 2
Qualitative 0
Quantitative 0; V 0
Qualitative 0
Quantitative macrophages 1(c); V 2
Qualitative 1
Quantitative 0; V 0
Qualitative 0
Quantitative
Glomeruli 0 tubules 1; V 0
Qualitative 1
Case 2 Quantitative 0; V 2
Qualitative 2
Quantitative 0; V 2
Qualitative 2
Quantitative macrophages 2(c); V 2
Qualitative 2
Quantitative hepatocytes 1 (c)
Bile ducts 1; V 1
Qualitative 1
Quantitative
Glomeruli 2 tubules 2; V 2
Qualitative 1
Case 3 Quantitative 0; V 1
Qualitative 0
Quantitative 0; V 1
Qualitative 1
Quantitative 0 (c); V 1
Qualitative 1
Quantitative 0; V 0
Qualitative 0
Quantitative
Glomeruli 0 tubules 1; V 0
Qualitative 1
Case 4 Quantitative 0; V 1
Qualitative 2
Quantitative 0; V 1
Qualitative 2
Quantitative 0 (c); V 2
Qualitative 1
Quantitative hepatocytes 1 (c)
Bile ducts 0; V 1
Qualitative 2
Quantitative
Glomeruli 2 tubules 0; V 1
Qualitative 2
Case 5 Quantitative 0; V 4
Qualitative 3
Quantitative 0; V 2
Qualitative 3
Quantitative macrophages 3 (c); V 3
Qualitative 2
Quantitative hepatocytes 2 (c)
Bile ducts 1; V 2
Qualitative 2
Quantitative
Glomeruli 2 tubules 3; V 3
Qualitative 2
Case 6 Quantitative 0; V 2
Qualitative 2
Quantitative 0; V 1
Qualitative 2
Quantitative macrophages 2 (c); V 2
Qualitative 2
Quantitative hepatocytes 0 (c)
Bile ducts 1; V 0
Qualitative 1
Quantitative
Glomeruli 1 tubules 0; V 1
Qualitative 1
Case 7 Quantitative 0; V 3
Qualitative 3
Quantitative 0; V 3
Qualitative 2
Quantitative macrophages 4 (c); V 4
Qualitative 3
Quantitative hepatocytes 3 (c)
Bile ducts 2; V 2
Qualitative 3
Quantitative
Glomeruli 4 tubules 3; V 2
Qualitative 3
Case 8 Quantitative 0; V 1
Qualitative 2
Quantitative 0; V 2
Qualitative 1
Quantitative macrophages 1 (c); V 2
Qualitative 2
Quantitative hepatocytes 1 (c)
Bile ducts 0; V 0
Qualitative 1
Quantitative
Glomeruli 2 tubules 2; V 2
Qualitative 1
Case 9 Quantitative 0; V 2
Qualitative 2
Quantitative 0; V 2
Qualitative 2
Quantitative macrophages 2(c); V 2
Qualitative 2
Quantitative hepatocytes 1 (c)
Bile ducts 1; V 1
Qualitative 1
Quantitative
Glomeruli 2 tubules 2; V 2
Qualitative 1
Case 10 Quantitative 0; V 1
Qualitative 0
Quantitative 0; V 1
Qualitative 1
Quantitative 0 (c); V 1
Qualitative 1
Quantitative 0; V 0
Qualitative 0
Quantitative
Glomeruli 0 tubules 1; V 0
Qualitative 1
Case 11 Quantitative 0; V 1
Qualitative 2
Quantitative 0; V 1
Qualitative 2
Quantitative 0 (c); V 2
Qualitative 1
Quantitative hepatocytes 1 (c)
Bile ducts 0; V 1
Qualitative 2
Quantitative
Glomeruli 2 tubules 0; V 1
Qualitative 2
Case 12 Quantitative 0; V 4
Qualitative 3
Quantitative 0; V 2
Qualitative 3
Quantitative macrophages 3 (c); V 3
Qualitative 2
Quantitative hepatocytes 2 (c)
Bile ducts 1; V 2
Qualitative 2
Quantitative
Glomeruli 2 tubules 3; V 3
Qualitative 2
Case 13 Quantitative 0; V 2
Qualitative 2
Quantitative 0; V 1
Qualitative 2
Quantitative macrophages 2 (c); V 2
Qualitative 2
Quantitative hepatocytes 0 (c)
Bile ducts 1; V 0
Qualitative 1
Quantitative
Glomeruli 1 tubules 0; V 1
Qualitative 1
Case 14 Quantitative 0; V 3
Qualitative 3
Quantitative 0; V 3
Qualitative 2
Quantitative macrophages 4 (c); V 4
Qualitative 3
Quantitative hepatocytes 3 (c)
Bile ducts 2; V 2
Qualitative 3
Quantitative
Glomeruli 4 tubules 3; V 2
Qualitative 3
V, intravascular staining; n, nuclear staining; c, cytoplasmic staining. For quantitative analysis, the TREM-1 stained cells were counted and divided by the total
number of cells and multiplied x 100. Immunohistochemical positivity score was defined as: 0, nuclear and/or cytoplasm staining absent; 1, nuclear and/or
cytoplasmic staining, 25%; 2, nuclear and/or cytoplasmic staining, 50%; 3, nuclear and/or cytoplasmic staining, 75%; 4, nuclear and/or cytoplasm staining,
100%. Immunohistochemical staining in blood vessel was quantified as: 0, absent; 1, low, 25%; 2, sufficient, 50%; 3, good, 75%; 4, considerable, 100%. Five
degrees of staining intensity were defined as: 0, absent; 1, low, 25%; 2, sufficient, 50%; 3, good, 75%; 4, considerable.
Figure 1. Box and whiskers plot of intravascular immunostaining by anti-TREM-1. Staining of the TREM-1 antibody in blood vessels
of kidney a) x 200, lung b) x 100, myocardium c) x 200, and brain d) x 200.
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Figure 2. a) TREM-1 staining (arrows) in cytoplasm of the myelomonocyte line. x 60. b) Weak TREM-1 staining (arrow) in
hepatocytes. x 200.
Figure 3. TREM-1 staining (arrows) in glomeruli a) x 100 and renal tubules (arrows) b) x 200.
Figure 4. Box and whiskers plot showing greater immunohistochemical reaction, both quantitatively and qualitatively, in the group
with documented ante-mortem s-TREM-1.
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Our findings for lung samples suggest that s-TREM-1
might be produced principally in the cells of the monocyte
line. Our findings for liver and kidney samples could be
related to the pathway of excretion of TREM-1. TREM-1
staining in kidney tubules, hepatocytes and liver ducts are a
normal physiological finding related to the elimination of
this protein from the circulation.
One limitations of our study is our use of a relatively
small number of subjects. Precise criteria, however, were
used for selecting subjects. Also, detailed immunohisto-
chemical studies TREM-1 are not available, which pre-
cluded comparison of our observations with others.
We believe that our measurement of s-TREM-1 may
be promising for making postmortem diagnoses of
sepsis. Our immunohistochemical technique currently
is more convenient compared to searching for
s-TREM-1 in serum or other biological fluids (Bellos
et al. 2018). It is important to compare the diagnostic
accuracy of s-TREM-1 with other biomarkers, such as
CRP and PCT. the variation in the threshold values
used (between 77.5 and 1707.35 pg/ml), however,
limit the value of these findings in clinical practice
(Bellos et al. 2018). Also TREM-1 could be stained in
patients with non-infective inflammatory diseases such
as psoriasis, ulcerative colitis or immune complex vas-
culitis. Moreover, TREM-1 could be stained in patients
affected by hemorrhagic shock, reperfusion injury or by
a peptic ulcer caused by H. pylori (Gibot et al. 2008;
Yasuda et al. 2008; Barbatzas and Pimentel 2011).
If s-TREM-1 staining can be found in cases un related
to sepsis, the anti-TREM-1 antibody could be combined
with an anti-procalcitonin and/or lactoferrin antibody to
produce considerable sensitivity and specificity in sepsis
related cases of death (Maiese et al. 2017; Galassi et al.
2018). Immunohistochemical staining using the anti-
TREM-1 antibody can be a useful method for postmor-
tem diagnosis of sepsis (Palmiere et al. 2013).
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